FOLD Financial Facts
General and administrative: 4.82MRestructuring charges: 0
See Full Income Statement
Deficit accumulated during the development stage: -336.35M
Accounts payable and accrued expenses: 6.43M
See Full Balance Sheet
Earnings History for Amicus Therapeutics, Inc. (FOLD)
|
Expand Research on FOLD
| Next EPS Date | 5/8/13 *Est. | EPS Growth Rate | +20.0% *Last Qtr. |
|---|---|---|---|
| Average EPS % Beat Rate | +13.0% | Revenue Growth Rate | -100.0% *Last Qtr. |
| Average % Move 1-Wk after EPS | -0.6% |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Estimize EPS/Revs | Gd. | % Since | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
5/4/11  |
 |
Q111 | -$0.39 | -$0.35 | -$0.04 | $6M | $1.24M | N/A / N/A | N/A | -53.3% | Details |
| 2/13/12 |
|
Q411 | -$0.25 | -$0.37 | +$0.12 | $922K | $6.06M | N/A / N/A | N/A | -50% | Details |
| 2/14/11 |
|
Q410 | -$0.48 | -$0.15 | -$0.33 | $922K | $9M | N/A / N/A | N/A | -49.3% | Details |
| 11/5/12 |
|
Q312 | -$0.31 | -$0.24 | -$0.07 | $5.8M | $8.82M | N/A / N/A | N/A | -33% | Details |
| 5/10/12 |
Q112 | -$0.35 | -$0.36 | +$0.01 | $7.8M | $7.52M | N/A / N/A | N/A | -27.3% | Details | |
| 3/12/13 | Q412 | -$0.20 | -$0.37 | +$0.17 | N/A | N/A | N/A / N/A | N/A | +11.4% | Details | |
| 11/1/11 |
|
Q311 | -$0.28 | -$0.33 | +$0.05 | $5.8M | $5.07M | N/A / N/A | N/A | +11.7% | Details |
